Email this article FTORAFUR IN COMBINATION WITH OXALIPLATIN AND IRINOTECAN IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER: PRELIMINARY RESULTS
- Authors: Dobrova N.V.1, Aratyunyan E.A.1, Polushkina I.N.1, Aliev V.A.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 7, No 4 (2017)
- Pages: 44-53
- Section: ORIGINAL REPORT
- Published: 27.02.2018
- URL: https://onco-surgery.info/jour/article/view/234
- DOI: https://doi.org/10.17650/2220-3478-2017-7-4-44-53
- ID: 234
Cite item
Full Text
Abstract
Objective: to develop an effective, well-tolerated, convenient for outpatient care (without installing a subclavian catheter) three-component treatment regimen that includes ftorafur – an original oral fluoropyrimidine drug.
Materials and methods. The study included 25 patients with disseminated colorectal cancer that have never received specific pharmacotherapy. We evaluated the efficacy and safety of a new first-line three-component treatment regimen with oxaliplatin + irinotecan + ftorafur. Patients in group 1 (n = 6) received this regimen for 3 weeks, whereas patients in group 2 (n = 19) received it for 2 weeks.
Results. Only preliminary results of the study are currently available. Median time to progression and overall survival are not yet estimated. Three (50 %) patients from group 1 achieved partial regression of metastases; 3 patients from this group had long-term (≥6 months) disease stabilization. Therapeutic effect (partial remission + long-term stabilization) was observed in all patients. Time without progression varied between 6 and 20 months. In group 2, therapeutic effect was estimated in 18 patients that received at least 2 courses of chemotherapy. Eight out of these 18 patients had partial response (2 of them underwent radical surgery); 8 patients had disease stabilization. Thus, 88.8 % of patients from group 2 responded to treatment. In the whole study population (both groups), response to treatment was achieved in 91 % of patients.
Conclusion. Our preliminary results suggest that the combination of oxaliplatin, irinotecan and ftorafur is safe and has an acceptable toxicity profile; therefore, it can be used in weakened patients.
Keywords
About the authors
N. V. Dobrova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: dobrova2008@rambler.ru
23 Kashirskoe Shosse, Moscow 115478, Russia
Russian FederationE. A. Aratyunyan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
23 Kashirskoe Shosse, Moscow 115478, Russia
Russian FederationI. N. Polushkina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
23 Kashirskoe Shosse, Moscow 115478, Russia
Russian FederationV. A. Aliev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
23 Kashirskoe Shosse, Moscow 115478, Russia
Russian FederationReferences
Supplementary files
